An updated Review on Therapeutic Potential of Entrectinib as a Promising TrK, ROS 1, and ALK Inhibitor in Solid Tumors and Lung Cancer
2021 ◽
pp. 413-421
Keyword(s):
Kinase C
◽
Entrectinib is a selective inhibitor of tyrosine kinases , tropomyosin receptor kinases that targets oncogenic rearrangements in Neurotropic Tyrosine Receptor kinase, c-ros oncogene 1 and Anaplastic lymphoma kinase used for the treatment of various solid tumors. Entrectinib gained its first worldwide approval in Japan in June 2019 for the treatment of NTRK fusion-positive, advanced or recurring solid tumours in adults and children. In august 15, 2019 drug got FDA approval for the treatment of solid tumors in adult and children aged 12 and above. This article summarizes current status of Entrectinib from ongoing clinical trails and ideal place for drug in therapy.
2019 ◽
Vol 37
(15_suppl)
◽
pp. TPS3150-TPS3150
◽
Keyword(s):
2010 ◽
Vol 7
(3)
◽
pp. 283-294
◽
2009 ◽
Vol 29
(10)
◽
pp. 1182-1185
◽
Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery
2020 ◽
Vol 17
(5)
◽
pp. 585-615
◽
2020 ◽
Vol 15
(4)
◽
pp. 321-331
◽
Keyword(s):